Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS

Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are primary glomerulopathies leading to proteinuria, known as podocytopathies, which share syndromic and morphological similarities. Morphological similarity occurs in cases of FSGS in which the sclerotic lesion was not sampl...

Full description

Bibliographic Details
Main Authors: Crislaine Aparecida da Silva, Liliane Silvano Araújo, Maria Luíza Gonçalves dos Reis Monteiro, Lívia Helena de Morais Pereira, Marcos Vinícius da Silva, Lúcio Roberto Cançado Castellano, Rosana Rosa Miranda Corrêa, Marlene Antônia dos Reis, Juliana Reis Machado
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.1155/2019/1070495
id doaj-19575d6cfff1417fa687f90fe8141d47
record_format Article
spelling doaj-19575d6cfff1417fa687f90fe8141d472020-11-25T01:30:20ZengHindawi LimitedDisease Markers0278-02401875-86302019-01-01201910.1155/2019/10704951070495Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGSCrislaine Aparecida da Silva0Liliane Silvano Araújo1Maria Luíza Gonçalves dos Reis Monteiro2Lívia Helena de Morais Pereira3Marcos Vinícius da Silva4Lúcio Roberto Cançado Castellano5Rosana Rosa Miranda Corrêa6Marlene Antônia dos Reis7Juliana Reis Machado8Discipline of General Pathology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, 38025-015 Uberaba, Minas Gerais, BrazilDiscipline of General Pathology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, 38025-015 Uberaba, Minas Gerais, BrazilDiscipline of General Pathology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, 38025-015 Uberaba, Minas Gerais, BrazilDiscipline of General Pathology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, 38025-015 Uberaba, Minas Gerais, BrazilDiscipline of Parasitology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Av. Getúlio Guaritá, No. 130, Nossa Senhora da Abadia, 38025-440 Uberaba, Minas Gerais, BrazilHuman Immunology Research and Education Group, Technical School of Health of Federal University of Paraíba, Cidade Universitária, 58059-900 João Pessoa, Paraíba, BrazilDiscipline of General Pathology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, 38025-015 Uberaba, Minas Gerais, BrazilDiscipline of General Pathology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, 38025-015 Uberaba, Minas Gerais, BrazilDiscipline of General Pathology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Praça Manoel Terra, 330, Nossa Senhora da Abadia, 38025-015 Uberaba, Minas Gerais, BrazilMinimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are primary glomerulopathies leading to proteinuria, known as podocytopathies, which share syndromic and morphological similarities. Morphological similarity occurs in cases of FSGS in which the sclerotic lesion was not sampled in renal biopsy, due to the focal nature of the disease. Differentiating these entities is very important, especially in cases of suspected FSGS but with sclerotic lesion not sampled, as they are diseases that apparently have different pathogenic mechanisms and prognosis. The difference in uPAR expression in situ among these two entities may be related to a distinct molecular mechanism involved in pathogenesis. Thus, finding biomarkers involved in the pathogenesis and that can also help in differential diagnosis is very relevant. The aim of this work was to evaluate the potential of urokinase-type plasminogen activator receptor (uPAR) as a biomarker in renal biopsies of patients with podocytopathies (n=38). Immunohistochemistry showed that FSGS (n=22) had increased uPAR expression in podocytes compared with both the MCD group (n=16; p=0.0368) and control group (n=21; p=0.0076). ROC curve (p=0.008) showed that this biomarker has 80.95% of specificity in biopsies of patients with FSGS. Therefore, uPAR presented a high specificity in cases of podocytopathies associated with sclerosis and it can be considered a potential biomarker for FSGS.http://dx.doi.org/10.1155/2019/1070495
collection DOAJ
language English
format Article
sources DOAJ
author Crislaine Aparecida da Silva
Liliane Silvano Araújo
Maria Luíza Gonçalves dos Reis Monteiro
Lívia Helena de Morais Pereira
Marcos Vinícius da Silva
Lúcio Roberto Cançado Castellano
Rosana Rosa Miranda Corrêa
Marlene Antônia dos Reis
Juliana Reis Machado
spellingShingle Crislaine Aparecida da Silva
Liliane Silvano Araújo
Maria Luíza Gonçalves dos Reis Monteiro
Lívia Helena de Morais Pereira
Marcos Vinícius da Silva
Lúcio Roberto Cançado Castellano
Rosana Rosa Miranda Corrêa
Marlene Antônia dos Reis
Juliana Reis Machado
Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS
Disease Markers
author_facet Crislaine Aparecida da Silva
Liliane Silvano Araújo
Maria Luíza Gonçalves dos Reis Monteiro
Lívia Helena de Morais Pereira
Marcos Vinícius da Silva
Lúcio Roberto Cançado Castellano
Rosana Rosa Miranda Corrêa
Marlene Antônia dos Reis
Juliana Reis Machado
author_sort Crislaine Aparecida da Silva
title Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS
title_short Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS
title_full Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS
title_fullStr Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS
title_full_unstemmed Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS
title_sort evaluation of the diagnostic potential of upar as a biomarker in renal biopsies of patients with fsgs
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2019-01-01
description Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are primary glomerulopathies leading to proteinuria, known as podocytopathies, which share syndromic and morphological similarities. Morphological similarity occurs in cases of FSGS in which the sclerotic lesion was not sampled in renal biopsy, due to the focal nature of the disease. Differentiating these entities is very important, especially in cases of suspected FSGS but with sclerotic lesion not sampled, as they are diseases that apparently have different pathogenic mechanisms and prognosis. The difference in uPAR expression in situ among these two entities may be related to a distinct molecular mechanism involved in pathogenesis. Thus, finding biomarkers involved in the pathogenesis and that can also help in differential diagnosis is very relevant. The aim of this work was to evaluate the potential of urokinase-type plasminogen activator receptor (uPAR) as a biomarker in renal biopsies of patients with podocytopathies (n=38). Immunohistochemistry showed that FSGS (n=22) had increased uPAR expression in podocytes compared with both the MCD group (n=16; p=0.0368) and control group (n=21; p=0.0076). ROC curve (p=0.008) showed that this biomarker has 80.95% of specificity in biopsies of patients with FSGS. Therefore, uPAR presented a high specificity in cases of podocytopathies associated with sclerosis and it can be considered a potential biomarker for FSGS.
url http://dx.doi.org/10.1155/2019/1070495
work_keys_str_mv AT crislaineaparecidadasilva evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT lilianesilvanoaraujo evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT marialuizagoncalvesdosreismonteiro evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT liviahelenademoraispereira evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT marcosviniciusdasilva evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT luciorobertocancadocastellano evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT rosanarosamirandacorrea evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT marleneantoniadosreis evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
AT julianareismachado evaluationofthediagnosticpotentialofuparasabiomarkerinrenalbiopsiesofpatientswithfsgs
_version_ 1725092066689548288